Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced its participation in the upcoming virtual H.C. Wainwright @ Home Fireside Chat Series. The event is scheduled for Monday, December 16, 2024, at 11:00 a.m. ET. The commercial stage specialty pharmaceutical company will provide a live webcast of the presentation, which will be accessible through their investor relations website. An archived version of the webcast will be made available on the company's website following the event for those unable to attend the live presentation.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha annunciato la sua partecipazione alla prossima serie di chat virtuali H.C. Wainwright @ Home Fireside Chat Series. L'evento è previsto per lunedì 16 dicembre 2024, alle 11:00 ET. La compagnia farmaceutica specializzata in fase commerciale fornirà una trasmissione in diretta della presentazione, che sarà accessibile attraverso il loro sito web per le relazioni con gli investitori. Una versione archiviata della trasmissione sarà disponibile sul sito web della compagnia dopo l'evento per coloro che non potranno partecipare alla presentazione dal vivo.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha anunciado su participación en la próxima serie de charlas virtuales H.C. Wainwright @ Home Fireside Chat Series. El evento está programado para el lunes 16 de diciembre de 2024, a las 11:00 a.m. ET. La compañía farmacéutica especializada en fase comercial ofrecerá una transmisión en vivo de la presentación, que será accesible a través de su sitio web de relaciones con inversores. Una versión archivada de la transmisión estará disponible en el sitio web de la compañía después del evento para aquellos que no puedan asistir a la presentación en vivo.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX)는 다가오는 가상 H.C. Wainwright @ Home Fireside Chat Series에 참여할 것을 발표했습니다. 이 행사는 2024년 12월 16일 월요일 오전 11:00 ET에 예정되어 있습니다. 상업 단계의 전문 제약 회사는 투자자 관계 웹사이트를 통해 접근 가능한 실시간 프레젠테이션 웹캐스트를 제공할 것입니다. 생중계에 참석할 수 없는 분들을 위해 행사 후 회사 웹사이트에서 웹캐스트의 보관 버전이 제공될 예정입니다.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) a annoncé sa participation à la prochaine série de discussions virtuelles H.C. Wainwright @ Home Fireside Chat Series. L'événement est prévu pour le lundi 16 décembre 2024, à 11h00 ET. L'entreprise pharmaceutique spécialisée en phase commerciale proposera une diffusion en direct de la présentation, accessible via son site web dédié aux relations investisseurs. Une version archivée de la diffusion sera disponible sur le site internet de l'entreprise après l'événement pour ceux qui ne peuvent pas assister à la présentation en direct.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) hat seine Teilnahme an der bevorstehenden virtuellen H.C. Wainwright @ Home Fireside Chat Series bekannt gegeben. Die Veranstaltung ist für Montag, den 16. Dezember 2024, um 11:00 Uhr ET geplant. Das Unternehmen, das auf Arzneimittel in der kommerziellen Phase spezialisiert ist, wird eine Live-Übertragung der Präsentation anbieten, die über seine Investor-Relations-Website zugänglich sein wird. Eine archivierte Version der Übertragung wird nach der Veranstaltung auf der Website des Unternehmens verfügbar sein für diejenigen, die nicht an der Live-Präsentation teilnehmen können.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET.
To access the live webcast, please visit: https://investors.fennecpharma.com/events-and-presentations/events. An archived replay of the webcast will be available on the Fennec website following the event.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI®. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate & Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When is Fennec Pharmaceuticals (FENC) presenting at the H.C. Wainwright Fireside Chat Series?
How can investors access Fennec Pharmaceuticals' (FENC) H.C. Wainwright presentation?
Will there be a replay available of Fennec Pharmaceuticals' (FENC) H.C. Wainwright presentation?
What stock exchanges is Fennec Pharmaceuticals listed on?
